EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Evofem Biosciences (NASDAQ: EVFM) reported strong growth for its hormone-free contraceptive Phexxi in Q2 2021, dispensing over 14,000 units and involving more than 5,400 healthcare providers. Notably, 60% of new users are aged 18 to 34, with many switching from hormonal methods. CEO Saundra Pelletier highlighted a growing trend among women prioritizing hormone-free options. Detailed metrics will be discussed in the upcoming earnings call in August, further solidifying Phexxi's position in women's reproductive health.

Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 a.m. ET. The presentation will be available via live webcast and archived for 30 days. The company focuses on developing products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi, launched in September 2020. Evofem is also evaluating the EVO100 candidate for preventing specific STIs in an ongoing Phase 3 clinical trial, EVOGUARD.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET. The presentation will focus on the commercialization of Evofem's hormone-free contraceptive Phexxi®, the Phase 3 clinical trial for EVO100 to prevent chlamydia and gonorrhea in women, and other initiatives. Interested participants can pre-register for the presentation at ldmicrojune2021.mysequire.com.

Evofem Biosciences, Inc. (NASDAQ: EVFM) has successfully closed a public offering of 50 million shares of common stock, raising approximately $46.6 million after expenses. The offering included warrants for an additional 50 million shares, with the underwriter granted a 30-day option for an extra 7.5 million shares and warrants. The proceeds will fund commercialization efforts for Phexxi, ongoing clinical trials for EVO100, and general corporate purposes. The offering was conducted under Evofem's effective shelf registration statement, and all securities were sold by the company.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the pricing of its underwritten public offering of 50 million shares of common stock and accompanying short-term warrants, priced at $1.00 per share. The offering is expected to generate gross proceeds of $50 million, with an additional $50 million possible from the full exercise of the warrants. The net proceeds will fund commercialization activities for Phexxi, the ongoing EVOGUARD Phase 3 trial for EVO100, and general corporate purposes. The offering is set to close on or about May 20, 2021.

Evofem Biosciences (NASDAQ: EVFM) announced a proposed underwritten public offering of common stock or pre-funded warrants, along with common warrants for each share sold. The offering is contingent on market conditions and may include a 30-day underwriter option for additional shares. Proceeds will be allocated to commercial activities for Phexxi, the ongoing EVOGUARD Phase 3 clinical trial, and general corporate purposes. The offering is made under an effective shelf registration statement filed with the SEC.

Evofem Biosciences (NASDAQ: EVFM) announced research findings on its investigational drug EVO100 aimed at preventing chlamydia and gonorrhea in women. These findings will be presented at the Virtual ISPOR 2021 conference from May 17 to 20, 2021. The study involved 21 women and highlighted the significance of product satisfaction and its correlation with adherence to EVO100. The pivotal Phase 3 trial, EVOGUARD, is ongoing with over 80 activated sites, expecting to complete enrollment by year-end 2021. Positive results may lead to a New Drug Application to the FDA by late 2022.

Evofem Biosciences (NASDAQ: EVFM) announced on May 12, 2021, that the FDA granted Fast Track designation for EVO100, aimed at preventing urogenital gonorrhea in women. This designation accelerates the development of new therapies for serious health needs. With over 600,000 gonorrhea cases reported in 2019, the need for a preventive solution is critical. EVO100 also holds prior Fast Track and Qualified Infectious Disease Product status for chlamydia prevention. A pivotal Phase 3 trial is underway, with positive results potentially leading to a New Drug Application by late 2022.

Evofem Biosciences (NASDAQ: EVFM) reported a significant increase in net revenue, reaching $1.1 million for Q1 2021, up from $0.2 million in Q4 2020 due to the success of its DTC campaign for Phexxi, which led to an 83% growth in total prescriptions. Operating expenses surged to $46 million, resulting in a net loss of $46.2 million, or $(0.56) per share. The company is focused on improving gross-to-net adjustments and is advancing the EVOGUARD Phase 3 trial for EVO100. Cash reserves were $45.3 million at the end of March 2021.